Skip to main content

Table 2 Number of DEGs involved in selected KEGG pathways at each age group. Values in the parentheses are Q-values of pathway enrichment test, and significant Q-values (< 0.1) are marked witha

From: Genome-wide RNAseq study of the molecular mechanisms underlying microglia activation in response to pathological tau perturbation in the rTg4510 tau transgenic animal model

Pathways Month 2 Month 4 Month 6 Month 8
NF-κB signaling 7 (9.69E-03a) 21 (8.74E-03a) 18 (2.44E-01) 24 (2.83E-03a)
cytokine-cytokine receptor interaction 11 (1.86E-02a) 42 (1.82E-02a) 53 (1.07E-02a) 49 (4.68E-03a)
Lysosome 4 (4.73E-01) 37 (3.96E-08a) 40 (1.13E-06a) 41 (8.58E-09a)
Alzheimer’s disease 3 (7.53E-01) 45 (1.41E-08a) 56 (2.20E-10a) 39 (1.51E-04a)
Parkinson’s disease 0 30 (2.75E-04a) 42 (3.43E-07a) 26 (2.51E-02a)
Huntington’s disease 0 33 (8.74E-03a) 47 (8.59E-05a) 27 (3.54E-01)
Oxidative phosphorylation 0 37 (1.41E-08a) 47 (4.71E-11a) 33 (3.82E-05a)
HIF-1 signaling pathway 3 (6.34E-01) 25 (1.12E-03a) 25 (2.51E-02a) 23 (2.26E-02a)
Phagosome 3 (7.91E-01) 31 (1.89E-03a) 45 (2.40E-04a) 43 (5.11E-05a)